{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-23-000036","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.427930+00:00","generated_at":"2026-06-08T17:49:18.596904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zymeworks reports 44% reduction in nine-month net loss to $104.2M; launches ZW251 IND candidate for HCC","bullets":["Nine-month net loss decreased 44% to $104.2M vs $185.1M same period 2022; revenue up 491% to $59.1M.","Cash resources $390.2M as of Sept 30, 2023; expected to fund operations through at least end of 2026.","ZW251, GPC3-targeted ADC for hepatocellular carcinoma, nominated as next IND candidate; filing expected 2H-2025.","Zanidatamab partner BeiGene presented Phase 1b/2 data: ORR 75.8%, mDOR 22.8 months, mPFS 16.7 months in first-line HER2+ GEA.","Termination of licensing agreement for zanidatamab zovodotin with BeiGene; Zymeworks regained APAC rights and plans Phase 2 study in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-23-000036","json":"https://secwatch.observer/filing/0001937653-23-000036.json","markdown":"https://secwatch.observer/filing/0001937653-23-000036.md","text":"https://secwatch.observer/filing/0001937653-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/0001937653-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/zyme-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:49:18.596904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"541eaa48ccd3045f73f64874c19855c0b1c58e0d","claim":"Zymeworks Inc. reported financial results for third quarter 2023.","evidence_excerpt":"On November 7, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000036/0001937653-23-000036-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}